Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Capricor Stock Rallies 20% on DMD Data Presentation Update
Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Solid Biosciences (SLDB) Gets a Buy From Piper Sandler
ITeos Therapeutics, Upstart Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Solid Biosciences to Participate at Upcoming Investor Conferences
Chardan Adjusts PT on Solid Biosciences to $15 From $6, Updates Thesis Ahead of Data Release for Gene Therapy Candidate SGT-003; Maintains Buy Rating
Express News | Solid Biosciences Inc : Chardan Capital Markets Raises Target Price to $15 From $6
Chardan Capital Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Chardan Capital analyst Geulah Livshits maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and adjusts the target price from $90 to $15.According to TipRanks data, the analyst has a success
Buy Rating Justified for Solid Biosciences Amid Promising Gene Therapy Advances
Solid Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q2 EPS Results.
Solid Biosciences Is Maintained at Overweight by Barclays
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
Solid Biosciences Analyst Ratings
Express News | Solid Biosciences : Barclays Cuts Target Price to $15 From $18
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright analyst Arthur He CFA maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and maintains the target price at $16.According to TipRanks data, the analyst has a success rate of 43.4
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Solid Biosciences (SLDB)
Buy Rating Affirmed for Solid Biosciences Amid Promising Early Data on SGT-003 DMD Therapy
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Barclays analyst Gena Wang maintains $Solid Biosciences(SLDB.US)$ with a buy rating, and adjusts the target price from $18 to $15.According to TipRanks data, the analyst has a success rate of 46.1%